NCT04525131View on ClinicalTrials.gov

Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 25, 2020

Primary Completion Date

December 30, 2022

Study Completion Date

June 30, 2023

Conditions
Bladder Cancer
Interventions
DRUG

CPX-POM

CPX-POM

Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

Sponsors

Lead Sponsor

CicloMed LLC
All Listed Sponsors
lead

CicloMed LLC

INDUSTRY

NCT04525131 - Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors | Biotech Hunter | Biotech Hunter